Diphenhydramine


First-generation H1 antihistamine + anticholinergic

An ethanolamine first-generation H1 antihistamine; the canonical sedating antihistamine and OTC sleep aid.

Abstract

Diphenhydramine (2-(diphenylmethoxy)-N,N-dimethylethanamine; CAS 58-73-1; molecular formula C17H21NO; molecular weight 255.36) is an ethanolamine first-generation H1 antihistamine developed at Parke-Davis and approved in 1946. The compound is the canonical sedating H1 blocker (Ki approximately 16 nM) with significant anticholinergic activity (M1-M5 antagonism, Ki approximately 70 nM). The combined activity produces sedation, dry mouth, blurred vision, and confusion (especially in elderly). Plasma half-life is approximately 4 to 8 hours. Approved indications: allergic conditions, motion sickness, parkinsonism, anaphylaxis. OTC sleep aid use in branded products (Tylenol PM, ZzzQuil) is widespread despite limited efficacy and concerning anticholinergic burden in elderly (associated with dementia risk in long-term use per BEERS criteria). The compound has dose-dependent abuse potential at high doses (deliriant effect from anticholinergic activity). Used as the canonical first-generation H1 antihistamine in research.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph